Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitor

A pharmaceutical dosage form comprising:

• N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide, a salt, a hydrate, or a solvate thereof;
• at least one pharmaceutically acceptable polymer comprising a copolymer of N-vinyl pyrrolidone;
• a single pharmaceutically acceptable solubilizer, said single pharmaceutically acceptable solubilizer being a tocopheryl compound having a polyalkylene glycol moiety;
• wherein the N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide, a salt, a hydrate, or a solvate thereof is dispersed within a solid dispersion product in a concentration from 0.5 to 40% by weight, the solid dispersion product further comprising from 40 to 97.5% by weight of the at least one pharmaceutically acceptable polymer and from 2 to 20% by weight of the single pharmaceutically acceptable solubilizer.